OTC: VASO

VASO Corp

CIK 0000839087 · Health Care · SIC 3845 · Electromedical Equipment

Small Revenue $89M Assets $83M as of Aug 1, 2026

Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.

Sign up free

Want to see a complete report first? Today's free report (RBLX 10-Q) is open in full — no account needed.

8-K Filed Jul 31, 2026 · Period ending Jul 31, 2026

Summary not yet generated.

8-K Filed Jul 23, 2026 · Period ending Jul 23, 2026

Summary not yet generated.

Partner

Trade VASO commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

10-Q Filed May 15, 2026 · Period ending Mar 31, 2026

Summary not yet generated.

8-K Filed May 8, 2026 · Period ending May 4, 2026

Summary not yet generated.

10-K Filed Mar 31, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

10-Q Filed Nov 14, 2025 · Period ending Sep 30, 2025

Summary not yet generated.

10-K Filed Mar 31, 2025 · Period ending Dec 31, 2024

Summary not yet generated.

10-K/A Filed May 12, 2020 · Period ending Dec 31, 2019

Summary not yet generated.

10-Q/A Filed Aug 27, 2010 · Period ending Feb 28, 2010

Summary not yet generated.

Latest financial statements

From 10-Q filed May 15, 2026 (period ending Mar 31, 2026). SEC XBRL (companyfacts) — not generated by the model.

SEC XBRL

Consolidated Statements of Operations (Unaudited)

Description Q1 ended Mar 31, 2026 Q3 ended Sep 30, 2025
Revenue:
Total revenue / net sales 19.4 22.7
Cost of revenue / cost of sales 7.8 8.8
Gross profit 11.6 13.9
Operating expenses:
Research and development 0.2 0.1
Selling, general and administrative 12.7 12.2
Total operating expenses 12.9 12.4
Operating income (1.3) 1.5
Other income/(expense), net 0.3 0.2
Income before income taxes (1.1) 1.7
Income tax expense/(benefit) (0.2) 0.04
Net income (0.9) 1.7
Basic earnings per share (0.01) 0.01
Diluted earnings per share (0.01) 0.01

Consolidated Balance Sheets (Unaudited)

Description Mar 31, 2026 Dec 31, 2025
Current assets:
Other receivables, net 21.5 15.9
Inventories 0.3 0.3
Prepaid expenses and other current assets 2.0 2.0
Other current assets 27.3 40.3
Total current assets 51.1 58.6
Property, plant and equipment, net 1.2 1.3
Operating lease right-of-use assets, net 2.1 1.5
Identifiable intangible assets, net 2.2 1.9
Goodwill 11.0 11.0
Deferred income taxes and other assets 8.2 8.0
Other long-term assets 7.2 6.2
TOTAL ASSETS 83.0 88.3
Current liabilities:
Accounts payable 3.9 4.0
Current portion of operating lease liabilities 1.1 0.9
Income taxes payable 0.7 0.8
Deferred revenue, current 18.6 19.0
Other current liabilities 6.1 12.1
Total current liabilities 30.6 36.8
Operating lease liabilities 1.0 0.6
Deferred income taxes and other liabilities 2.0 1.9
Shareholders' equity:
Common stock 0.2 0.2
Capital in excess of stated value 62.1 62.1
Accumulated other comprehensive income (loss) (0.3) (0.3)
Retained earnings (deficit) (33.4) (32.5)
Total shareholders' equity 28.6 29.4
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 83.0 88.3

Consolidated Statements of Cash Flows (Unaudited)

Description Q1 ended Mar 31, 2026 Nine months ended Sep 30, 2025
Operating Activities:
Net cash from operating activities (12.6) 9.0
Investing Activities:
Net cash from investing activities (0.5) (0.6)
Financing Activities:
Net increase/(decrease) in cash (13.1) 8.6

Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗